- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for subjects with mHSPC.
Inclusion criteria
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)